Sponsor

2013/03/06

Make Money Off My Misery

Having trouble viewing this e-mail? Click here to view in a web browser.
Investment U Plus - Turning Principles Into Profits
    Issue #1984

Sponsored

Blowing The Whistle On Big Oil... An Important Map And Your Chance To Cash In!

Pictured below is a map many Americans have never seen.

That's a shame, because today it holds one of the best profit opportunities the market has to offer.

Big oil knows this map well - heck, it's one of the reasons they always seem to turn a profit.

Today, thanks to a little-known loophole, you could start grabbing your share of the payouts too. Consider it your chance to get a little payback at the pump - finally, right?!

To see what I mean, click the map below...


Make Money Off My Misery
by Marc Lichtenfeld, Associate Investment Strategist
Wednesday, March 6, 2013
 

The following conversation took place between my wife and me a few months ago.

Mrs. L: I really think you should get a flu shot this year.

Me: I've never gotten one before and I've never come down with the flu.

Mrs. L.: It's supposed to be a really bad flu this season.

Me: I'm Superman, I don't get the flu.

I'm sure you can guess what happened.

I made it through most of flu season unscathed, as friends and family around me dropped like bad guys in a video game. Meanwhile, I was eating right, exercising and getting enough sleep. No way the flu was going to get me and my Clark Kent-like immune system.

And then it did. Last week.

I was as sick as I've ever been. I don't remember Thursday.

Fortunately, I'm on the mend and back to thinking about stocks.

And not surprisingly, an area I'm thinking about is flu stocks.

Even in my delirium, I knew there were big bucks in some stocks that have products related to the flu. When my wife called from the pharmacy to tell me that my Tamiflu prescription was going to be $105 (and that's with health insurance), I knew someone was making a bundle off my misery.

Roche Holdings (OTC: RHHBY) - The beautiful people who make Tamiflu. Two doses and I was on the road to recovery. It was worth every penny of that $105.

Tamiflu sales are expected to more than double this flu season to $750 million from $350 million last year. Roche is a huge company with $45 billion in sales, so the growth in Tamiflu won't move the needle much. But it can in the future if there's a pandemic. In 2009, sales hit $3 billion as governments stockpiled Tamiflu on pandemic fears.

Sanofi (NYSE: SNY) - The smart people whose product I should have used. Sanofi is the largest flu vaccine provider in the United States. In 2012, flu vaccines brought in $884 million in sales. GlaxoSmithKline (NYSE: GSK) and Novartis (NYSE: NVS) also make flu vaccines.

Sponsored

The Most Profitable Company in the History of the World?

Standard Oil... Saudi Aramco... The Dutch East India Company... These companies were bigger and more profitable than any single company on the planet today.

But one company could be on the verge of joining their ranks. It's already more profitable than just about every company on the globe. And yet, you've likely never heard of it. Details here.

It's estimated the flu vaccines were effective just slightly more than half the time this year. So drug and biotech companies are always searching for a better vaccine. And investors are looking for the next great company to come up with that vaccine.

There are several small companies working on the vaccines, like Inovio (NYSE: INO) and Vical (Nasdaq: VICL), but I would stay with the big pharmaceutical companies on this one. The small names don't have a good track record of being able to bring a product to the market. And even if they succeed, they would have to partner with a larger company for its sales network.

That doesn't mean you should never invest in a small-cap biotech company. Many have some great breakthroughs in various diseases, especially cancer. But many of these indications are wide open markets, or the drug is such an improvement that the company will take significant market share.

With flu vaccines dominated by big pharma, it will be tough for a small fry to break in and be successful.

Walgreens (NYSE: WAG) - Not only can you buy your Tamiflu, decongestants and ibuprofen at Walgreens, you can also get your flu shot at the pharmacy. In fact, 6.9 million people did as of January 31. That compares to 5.5 million the year before. And if those people are already in the store, chances are they're also picking up a box of band-aids, a two-liter bottle of soda, or some other household items they may need. In fact, Walgreens reported a strong 6% increase in sales in January.

Pilgrim's Pride (Nasdaq: PPC) - While the Tamiflu appeared to help me, it might have just been a coincidence. After all, I'd been eating homemade chicken soup for several days prior.

Pilgrim's Pride processes about 9.5 billion pounds of chicken annually. The company offers fresh and frozen whole chickens and parts.

While Pilgrim's isn't exactly a biotech or pharma company, its products are used to make the best medicine I know of.

And it's not just an old wives' tale. Several medical studies have shown that chicken soup actually does help. One study out of the University of Nebraska Medical Center concluded that chicken soup stopped the movement of white blood cells that fight infection. By inhibiting their movement, upper respiratory symptoms were reduced. Another study showed that chicken soup increased air flow in the nasal cavity.

Next year, the vaccine makers can count on me to add one more to their rolls. And I'm going early. As much as I loved the Tamiflu, I'd prefer not to have to take it again.

Good Investing,

Marc

Editor's Note: Last week Marc wrote about why the companies providing the picks and shovels to speculative biotech companies were some of the safest bets in the sector.

Our favorite company in the space could hand early investors life-changing gains with its revolutionary new way to create billion-dollar drugs. After four years of research on this single company, Marc is finally pulling the trigger. For more information, click here.


           


Market Metrics

Reaching a Milestone

As the world praised the Dow for reaching a fresh high this week, I turned my attention to another major breakthrough. For the first time in more than a generation, the United States is not the world's top oil importer.

That tarnished crown now belongs to China.

According to the latest data, America's net imports of crude clocked in at 5.98 million barrels per day in December. But China was thirstier. Its net imports tallied 6.12 million barrels per day.

It's not a new trend - but then again, neither is the rip-roaring Dow - but the chart proves we've reached quite the milestone.

-Andrew Snyder

Click here to view the full chart.



RECENT ARTICLES
How to Save (Make) Money on High Gasoline Prices Dave Fessler identifies a sector and company that are bound to reap high rewards as long as gas is expensive...

Where to Find the Best Companies in Biotech Marc Lichtenfeld shows where to find some of the stronger, less speculative biotech companies...

The World's Most Unstoppable Trend Matthew Carr looks at one trend that will NEVER die. And these four stocks should continue to profit...

S&P's $5 Billion Lawsuit: Why it Matters and What to Do Earlier this month, the U.S. Department of Justice announced it was suing Standard & Poor's for $5 billion. Find out why it matters to you and your portfolio...






An Emerging Natural Gas Leader...


Sponsored

The Stock About to "Rock" Your Financial World

Thanks to a newly discovered "super substance," you could turn $9,000 into a small fortune. In short, a tiny American company is about to revolutionize all smart phones and HDTVs using this material. They hold key patents on it, yet oddly it's based on a common rock! At around $9 a share today, even a small stake in this company could catapult into a windfall. Details here.


Wealthy Retirement

The Safety Net: Icahn's Latest Target

Corporate Cash: You Deserve it More Than They Do

The Safety Net: A Choice Between Parent and Child

How to Retire With No Regrets


 

˜ SHARE INVESTMENT U ˜
If you enjoy reading Investment U, why not share it with your family and friends?
Simply send them this link, so they can sign up (for free, of course).

˜ QUESTIONS ˜
Republish Investment U on your website or blog for free. Learn how.
Have a question for our editorial team? Contact us.


© 2013 Investment U All Rights Reserved
Investment U | 105 West Monument Street | Baltimore, MD 21201
North America: 1 855 402 3939; Fax: 1 410 223 2650 International: +1 410 864 2529; Fax: +1 410 223 2650
E-mail: CustomerService@InvestmentUInfo.com | Website: www.InvestmentU.com
Disclaimer Information
and Privacy Policy

Note: You are receiving this e-mail as a part of your subscription to Investment U .
Keep the e-mails you value from falling into your spam folder, Whitelist Investment U

To manage your account or stop receiving Investment U, click here.
To cancel by mail or for any other subscription issues, write us at:
Investment U | Attn: Member Services | 105 West Monument Street | Baltimore, MD 21201

Nothing in this e-mail should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice.

We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

You're receiving this message because you subscribe to the Investment U e-letter. If you wish to post a comment on any of our articles, or contact our Customer Service team, please see the instructions above. Do not reply directly to this e-mail, as your message will not be read or answered. Also, please keep in mind that securities laws prevent us from issuing personal investment advice to our readers. We're prohibited from answering such questions or giving that information via e-mail or over the phone.

Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Investment U. 105 W. Monument Street, Baltimore MD 21201

No comments:

Post a Comment

Keep a civil tongue.

Label Cloud

Technology (1464) News (793) Military (646) Microsoft (542) Business (487) Software (394) Developer (382) Music (360) Books (357) Audio (316) Government (308) Security (300) Love (262) Apple (242) Storage (236) Dungeons and Dragons (228) Funny (209) Google (194) Cooking (187) Yahoo (186) Mobile (179) Adobe (177) Wishlist (159) AMD (155) Education (151) Drugs (145) Astrology (139) Local (137) Art (134) Investing (127) Shopping (124) Hardware (120) Movies (119) Sports (109) Neatorama (94) Blogger (93) Christian (67) Mozilla (61) Dictionary (59) Science (59) Entertainment (50) Jewelry (50) Pharmacy (50) Weather (48) Video Games (44) Television (36) VoIP (25) meta (23) Holidays (14)

Popular Posts (Last 7 Days)